{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000014","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.592543+00:00","generated_at":"2026-05-16T01:09:42.676915+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Summit FY25 GAAP net loss $1.08B, BLA accepted with PDUFA Nov 14, HARMONi-3 interim PFS Q2 2026","bullets":["GAAP net loss $1,079.6M ($1.44/sh) vs $221.3M ($0.31/sh) FY24; non-GAAP net loss $347.2M ($0.46/sh).","Cash and equivalents $713.4M at Dec 31, 2025, up from $412.3M at Dec 31, 2024.","FDA accepted BLA for ivonescimab+chemo in EGFR-mutated NSCLC; PDUFA goal date Nov 14, 2026.","HARMONi-3 squamous cohort screening complete; interim PFS analysis planned Q2 2026; final PFS H2 2026.","New Phase III ILLUMINE study (GORTEC) in HNSCC to initiate; first patient expected early Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000014","json":"https://secwatch.observer/filing/0001599298-26-000014.json","markdown":"https://secwatch.observer/filing/0001599298-26-000014.md","text":"https://secwatch.observer/filing/0001599298-26-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000014/0001599298-26-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000014/smmt-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:09:42.676915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}